Priya Sapra, SHYFT’s SVP, Product & Customer Engagement, talks to Pharmaceutical Commerce about SHYFT’s recent selection by Tetraphase Pharmaceuticals to support data and analytics for commercial launch readiness. SHYFT’s Platform will support the anticipated commercial launch of eravacycline, Tetraphase’s  lead antibiotic candidate developed to address multidrug-resistant bacteria.

Read more ->